CJC-1295 without DAC 5mg + IPA 5mg

CJC-1295 without DAC 5mg + IPA 5mg

Overview

This peptide blend combines CJC-1295 without DAC (5mg) and Ipamorelin (IPA, 5mg), two synergistic growth hormone–releasing peptides (GHRPs). Together, they are studied for their ability to stimulate natural growth hormone release, support recovery, and promote lean muscle development. This formulation is intended strictly for laboratory research use only and is not FDA-approved for human consumption.

Key Components

• CJC-1295 without DAC (5mg)
  • A synthetic analog of growth hormone–releasing hormone (GHRH).
  • Short-acting (without DAC), allowing for more controlled and pulsatile GH release.
  • Studied for its role in stimulating pituitary function and enhancing recovery.
• Ipamorelin (IPA, 5mg)

• A selective growth hormone secretagogue.
• Known for stimulating GH release without significantly affecting cortisol or prolactin.
• Investigated for muscle growth, fat reduction, and improved sleep quality.

Benefits in Research Context

• Synergistic GH Release: Combination enhances natural growth hormone pulses more effectively than either peptide alone.
• Muscle & Recovery Support: Studied for promoting lean muscle development and faster recovery from exercise or injury.
• Fat Metabolism: May aid in reducing body fat through improved metabolic activity.
• Anti-Aging Potential: Growth hormone stimulation is linked to improved skin elasticity, energy, and vitality in research models.

Risks & Considerations

• Research Use Only: Not FDA-approved for human consumption; intended strictly for laboratory studies.
• Potential Side Effects: Limited data; headaches, water retention, or injection site irritation have been reported in peptide studies.
• Short Half-Life: CJC-1295 without DAC requires more frequent dosing in research compared to DAC-based versions.
• Long-Term Safety Unknown: More clinical trials are needed to confirm efficacy and safety.